Reivindicaciones
1. A polymeric nanocapsule which comprises: a. A polymeric shell; and b. one or more bioactive molecules encapsulated or embedded in the polymeric shell, wherein the polymeric shell of a) comprises: - at least two structural monomers of formula I <img class="EMIRef" id="588794782-ib0003" /> wherein in the first structural monomer R<1>, R<2>, and R<3>, are hydrogen or C<1> to C<4> alkyl groups, X is NH, and R4 is -H; wherein in the second structural monomer R<1>, R<2>, and R<3>, are hydrogen or C<1> to C<4> alkyl groups, X is O, and -R<4> is a C<1> to C<4> -alkyl-NH2; and - at least one degradable and at least one non-degradable cross-linker of Formula II <img class="EMIRef" id="588794782-ib0004" /> wherein in the degradable cross-linker R<1>, R<2>, R<3>, R<5>, R<5> and R<7> a are hydrogen or C<1> to C<4> alkyl groups, R<4> is a C<1> to C<4> alkyl group, and X is O; and wherein in the non-degradable cross-linker R<1>, R<2>, R<3>, R<5>, R<6> and R<7> a are hydrogen or C<1> to C<4> alkyl groups, R<4> is a C<1> to C<4> alkyl group, and X is NH; wherein the molar ratio between the at least one degradable and the at least one non-degradable cross-linkers is in the range from about a 1:0.8 ratio to about a 1:1.2 ratio; and wherein the molar ratio between the first structural monomers and the second structural monomers is in the range from about a 1:0.66 ratio to about a 1:1 ratio as long as the molar concentration of the first structural monomers is at least equal or higher than the molar concentration by weight of the second structural monomers; and wherein the molar ratio between the monomers and the cross-linkers is in ranges from about a 1:0.04 ratio to about a 1:0.20 ratio. 2. The polymeric nanocapsule, according to claim 1, wherein: a. the molar ratio between the at least one degradable and the at least one non-degradable cross-linkers is in the range from about a 1:0.9 ratio to about a 1:1.1 ratio; b. wherein the molar ratio between the first structural monomers and the second structural monomers is in the range from about a 1:0.7 ratio to about a 1:0.9 ratio; and c. wherein the molar ratio between the monomers and the cross-linkers is in the range from about a 1:0.06 ratio to about a 1:0.17 ratio. 3. The polymeric nanocapsule, according to claim 1, wherein the molar ratio between the first structural monomer/second structural monomer/degradable cross-linker/non-degradable cross-linker is in the range from about a 7:6:1:1 ratio to about a 8:6:0.5:0.5. 4. The polymeric nanocapsule, according to claim 1, wherein the molar ratio between the first structural monomer/second structural monomer/degradable cross-linker/non-degradable cross-linker is about a 7:6:1:1. 5. The polymeric nanocapsule according to any of claims 1 to 4, wherein the bioactive molecule is a metal and/or serine protease, such as collagenase and/or trypsin activity. 6. The polymeric nanocapsule, according to any of claims 1 to 4, wherein the bioactive molecule is collagenase. 7. The polymeric nanocapsule, according to any of claims 1 to 6, wherein in the degradable cross-linker R<1>, R<2>, R<3>, R<5>, R<5> and R<7> a are hydrogen and R4 is a C<1> to C<2> alkyl group, and X is O; and wherein in the non-degradable cross-linker R<1>, R<2>, R<3>, R<5>, R<6> and R<7> a are hydrogen and R4 is a C<1> to C<2> alkyl group, and X is NH. 8. The polymeric nanocapsule, according to any of claims 1 to 7, wherein in the second structural monomer R<1>, R<2>, and R<3>, are hydrogen, X is O, and -R<4> is a C<1> to C<2> -alkyl-NH2. 9. The polymeric nanocapsule according to any of claims 1 to 8, wherein the degradable cross-linker is Ethyleneglycol dimethacrylate (EG) and the non-degradable cross-linker is bismethacrylamide (MBA). 10. The polymeric nanocapsule according to any of claims 1 to 8, wherein the first structural monomer is Acrylamide (AA) and the second structural monomer is 2-aminoethylmethacrylate hydrochloride (AM). 11. The polymeric nanocapsule according to any of claims 1 to 8, wherein the degradable cross-linker is Ethyleneglycol dimethacrylate (EG) and the non-degradable cross-linker is bismethacrylamide (MBA), and wherein the first structural monomer is Acrylamide (AA) and the second structural monomer is 2-aminoethylmethacrylate hydrochloride (AM). 12. The polymeric nanocapsule according to claim 11, wherein the molar ratio between the first structural monomer/second structural monomer/degradable cross-linker/non-degradable cross-linker is in ranges from about a 7:6:1:1 ratio to about a 8:6:0.5:0.5. 13. The polymeric nanocapsule according to claim 12, wherein the bioactive molecule is collagenase. 14. Method for obtaining the nanocapsule of any of claims 1 to 13, wherein the method comprises: f) Dissolving the monomers and cross-linkers in the presence of the bioactive molecule; g) Stirring the suspension a), preferably at room temperature (about 25°C), during 10 min in order to provide time for the adsorption of the monomers on the biomolecule surface; h) Adding a mixture of radical initiators, which is ammonium persulfate (APS) and N,N,N',N'-Tetramethylethylenediamine (TMEDA) in a molar ratio 1:2 between them and in a molar relation 1:200 to 1:500 protein:APS, in order to start the radical polymerization process. i) Stirring the mixture. j) Isolation of the nanocapsules. 15. Use of the polymeric nanocapsules of any of claims 1 to 13, as a cosmetic of pharmaceutical carrier of active ingredients. 16. Use of the polymeric nanocapsules of any of claims 1 to 13, as a cosmetic and/or pharmaceutical carrier of bioactive molecules. 17. Use of the polymeric nanocapsules of any of claims 1 to 13, as a cosmetic and/or pharmaceutical carrier of metal and/or serine proteases, such as collagenase and/or trypsin activity. 18. A pharmaceutical composition comprising the polymeric nanocapsules of any of claims 1 to 13, for use in the treatment of skin diseases via a topical administration, preferably to the skin, of metal and/or serine proteases, such as collagenase and/or trypsin activity. 19. The pharmaceutical composition for use of claim 18, wherein said skin diseases are fibrotic diseases caused by an elevated production of collagen selected from the list consisting of intra-vertebral disc herniaton, arterial occlusions, uterine fibroid, degradation of human retained placenta, nipple pain, glaucoma, vitrectomy, burns, abnormal wound healing and keloids, as well as Dupuytren and Peyronie diseases. 20. A cosmetic composition comprising the polymeric nanocapsules of any of claims 1 to 13. 21. The use of the cosmetic composition of claim 20, as a vehicle or carrier of bioactive molecules such as metal and/or serine protease, such as collagenase and/or trypsin activity to the skin. 22. The use according to claim 21, wherein said skin is affected by a fibrotic disease caused by an elevated production of collagen
